Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Michael R. Hayden Acquires 5,000 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Michael R. Hayden bought 5,000 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $36.22 per share, for a total transaction of $181,100.00. Following the completion of the purchase, the director now directly owns 35,219 shares in the company, valued at approximately $1,275,632.18. This represents a 16.55 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ionis Pharmaceuticals Stock Down 1.2 %

Ionis Pharmaceuticals stock opened at $35.91 on Friday. The business has a fifty day moving average price of $37.21 and a 200-day moving average price of $42.16. Ionis Pharmaceuticals, Inc. has a 1-year low of $33.33 and a 1-year high of $54.44. The stock has a market capitalization of $5.67 billion, a price-to-earnings ratio of -14.72 and a beta of 0.35. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in shares of Ionis Pharmaceuticals by 83.9% in the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after purchasing an additional 303 shares during the last quarter. nVerses Capital LLC purchased a new position in shares of Ionis Pharmaceuticals in the second quarter worth $29,000. Itau Unibanco Holding S.A. purchased a new position in shares of Ionis Pharmaceuticals in the second quarter worth $37,000. Capital Performance Advisors LLP acquired a new stake in shares of Ionis Pharmaceuticals during the third quarter worth $40,000. Finally, Prospera Private Wealth LLC purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at $42,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Wells Fargo & Company dropped their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. Guggenheim dropped their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, October 9th. Needham & Company LLC restated a “buy” rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, September 26th. Finally, StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $60.65.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.